PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12139305

Functional proteomics: mapping protein-protein interactions and pathways.

Daniel Figeys
View original source ↗Export metadata ↓

Abstract

The function of a protein is defined by its interactions with other proteins and molecules. Mapping of protein interactions can highlight new functionalities for a known protein or can even define the function of novel proteins. With the draft sequence of the human genome now available, it is possible to perform high-throughput mapping of protein-protein interactions in humans, which is termed as functional proteomics. The developments in functional proteomics are particularly timely since pharmaceutical companies are searching for technologies that will strengthen their genomic efforts and prioritize their drug discovery pipeline. In this article we review recent developments in functional proteomics.

Explore related subjects

Drug DesignGenome, HumanHumansMass SpectrometryPhosphorylationProtein Interaction MappingProtein Processing, Post-TranslationalProteomeProteomicsTwo-Hybrid System TechniquesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Daniel Figeys. 2002. Functional proteomics: mapping protein-protein interactions and pathways.. https://pubmed.ncbi.nlm.nih.gov/12139305/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study.

The p38 protein kinase is a serine-threonine mitogen activated protein kinase, which plays an important role in inflammation and arthritis. A combined study of 3D-QSAR and molecular docking has been undertaken to explore the structural insights of pyrazolyl urea p38 kinase inhibitors. The 3D-QSAR studies involved comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA). The best CoMFA model was derived from the atom fit alignment with a cross-validated r (2 )(q (2)) value of 0.516 and conventional r (2) of 0.950, while the best CoMSIA model yielded a q (2) of 0.455 and r (2) of 0.979 (39 molecules in training set, 9 molecules in test set). The CoMFA and CoMSIA contour maps generated from these models provided inklings about the influence of interactive molecular fields in the space on the activity. GOLD, Sybyl (FlexX) and AutoDock docking protocols were exercised to explore the protein-inhibitor interactions. The integration of 3D-QSAR and molecular docking has proffered essential structural features of pyrazolyl urea inhibitors and also strategies to design new potent analogues with enhanced activity.

Drug Design↗